Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14030-

  Sarkar, Debalina ^a   Biswas, Moanaro ^a   Liao, Gongxian ^b   Seay, Howard R ^a   Perrin, George Q ^a   Markusic, David M ^a   Hoffman, Brad E ^a   Brusko, Todd M ^a   Terhorst, Cox ^b   Herzog, Roland W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT BLOOD CLOTTING FACTOR 8; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; HEMOPHILIA A; HEMOPHILIA B; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TREATMENT DURATION;

EID: 84948774220     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.30     Document Type: Article

References (51)

1. 1 Sakaguchi, S, Miyara, M, Costantino, CM, Hafler, DA, FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10 (2010), 490–500.
2. 2 Brusko, TM, Putnam, AL, Bluestone, JA, Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 223 (2008), 371–390.
3. 3 Tang, Q, Bluestone, JA, Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med 3 (2013), 1–15.
4. 4 Miao, CH, Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 3 (2010), 469–483.
5. 5 Annoni, A, Brown, BD, Cantore, A, Sergi, LS, Naldini, L, Roncarolo, MG, In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 114 (2009), 5152–5161.
6. 6 Cao, O, Dobrzynski, E, Wang, L, Nayak, S, Mingle, B, Terhorst, C, et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110 (2007), 1132–1140.
7. 7 Skupsky, J, Zhang, AH, Su, Y, Scott, DW, B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Mol Ther 18 (2010), 1527–1535.
8. 8 Brunstein, CG, Miller, JS, Cao, Q, McKenna, DH, Hippen, KL, Curtsinger, J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117 (2011), 1061–1070.
9. 9 Edinger, M, Hoffmann, P, Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 23 (2011), 679–684.
10. 10 Marek-Trzonkowska, N, Mysliwiec, M, Dobyszuk, A, Grabowska, M, Techmanska, I, Juscinska, J, et al. Administration of CD4+CD25highCD127- regulatory T cells preserves ß-cell function in type 1 diabetes in children. Diabetes Care 35 (2012), 1817–1820.
11. 11 Trzonkowski, P, Bieniaszewska, M, Juscinska, J, Dobyszuk, A, Krzystyniak, A, Marek, N, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol 133 (2009), 22–26.
12. 12 Bacchetta, R, Lucarelli, B, Sartirana, C, Gregori, S, Lupo Stanghellini, MT, Miqueu, P, et al. Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Front Immunol, 5, 2014, 16.
13. 13 Desreumaux, P, Foussat, A, Allez, M, Beaugerie, L, Hébuterne, X, Bouhnik, Y, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology, 143, 2012, 1207 17.e1.
14. 14 Gagliani, N, Magnani, CF, Huber, S, Gianolini, ME, Pala, M, Licona-Limon, P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 19 (2013), 739–746.
15. 15 Markusic, DM, Hoffman, BE, Perrin, GQ, Nayak, S, Wang, X, LoDuca, PA, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med 5 (2013), 1698–1709.
16. 16 Nayak, S, Cao, O, Hoffman, BE, Cooper, M, Zhou, S, Atkinson, MA, et al. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J Thromb Haemost 7 (2009), 1523–1532.
17. 17 Chambost, H, Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia 16:suppl. 2 (2010), 10–15.
18. 18 Kruse-Jarres, R, Inhibitors: our greatest challenge. Can we minimize the incidence?. Haemophilia 19:suppl. 1 (2013), 2–7.
19. 19 Scott, DW, Lozier, JN, Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. Br J Haematol 156 (2012), 295–302.
20. 20 Scott, DW, Pratt, KP, Miao, CH, Progress toward inducing immunologic tolerance to factor VIII. Blood 121 (2013), 4449–4456.
21. 21 Herzog, RW, Dobrzynski, E, Immune implications of gene therapy for hemophilia. Semin Thromb Hemost 30 (2004), 215–226.
22. 22 Riley, JL, June, CH, Blazar, BR, Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30 (2009), 656–665.
23. 23 Scott, DW, T regulatory cells turn on T regulatory cells. Blood 114 (2009), 3975–3976.
24. 24 Miao, CH, Harmeling, BR, Ziegler, SF, Yen, BC, Torgerson, T, Chen, L, et al. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. Blood 114 (2009), 4034–4044.
25. 25 Ermann, J, Hoffmann, P, Edinger, M, Dutt, S, Blankenberg, FG, Higgins, JP, et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 105 (2005), 2220–2226.
26. 26 Lan, Q, Zhou, X, Fan, H, Chen, M, Wang, J, Ryffel, B, et al. Polyclonal CD4+Foxp3+ Treg cells induce TGFß-dependent tolerogenic dendritic cells that suppress the murine lupus-like syndrome. J Mol Cell Biol 4 (2012), 409–419.
27. 27 Di Ianni, M, Falzetti, F, Carotti, A, Terenzi, A, Castellino, F, Bonifacio, E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117 (2011), 3921–3928.
28. 28 Hoffmann, P, Boeld, TJ, Eder, R, Huehn, J, Floess, S, Wieczorek, G, et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 39 (2009), 1088–1097.
29. 29 Chai, JG, Coe, D, Chen, D, Simpson, E, Dyson, J, Scott, D, In vitro expansion improves in vivo regulation by CD4+CD25+ regulatory T cells. J Immunol 180 (2008), 858–869.
30. 30 Battaglia, M, Stabilini, A, Tresoldi, E, Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol Biol 821 (2012), 279–293.
31. 31 Tresoldi, E, Dell'Albani, I, Stabilini, A, Jofra, T, Valle, A, Gagliani, N, et al. Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica 96 (2011), 1357–1365.
32. 32 Hippen, KL, Merkel, SC, Schirm, DK, Sieben, CM, Sumstad, D, Kadidlo, DM, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med, 3, 2011, 83ra41.
33. 33 Golovina, TN, Mikheeva, T, Brusko, TM, Blazar, BR, Bluestone, JA, Riley, JL, Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS ONE, 6, 2011, e15868.
34. 34 Hippen, KL, Harker-Murray, P, Porter, SB, Merkel, SC, Londer, A, Taylor, DK, et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112 (2008), 2847–2857.
35. 35 Putnam, AL, Safinia, N, Medvec, A, Laszkowska, M, Wray, M, Mintz, MA, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 13 (2013), 3010–3020.
36. 36 Ukena, SN, Höpting, M, Velaga, S, Ivanyi, P, Grosse, J, Baron, U, et al. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity. Exp Hematol 39 (2011), 1152–1160.
37. 37 Liao, G, Nayak, S, Regueiro, JR, Berger, SB, Detre, C, Romero, X, et al. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells. Int Immunol 22 (2010), 259–270.
38. 38 Pasquet, L, Douet, JY, Sparwasser, T, Romagnoli, P, van Meerwijk, JP, Long-term prevention of chronic allograft rejection by regulatory T-cell immunotherapy involves host Foxp3-expressing T cells. Blood 121 (2013), 4303–4310.
39. 39 Gross, DA, Chappert, P, Leboeuf, M, Monteilhet, V, Van Wittenberghe, L, Danos, O, et al. Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products. Blood 108 (2006), 1841–1848.
40. 40 Gross, DA, Leboeuf, M, Gjata, B, Danos, O, Davoust, J, CD4+CD25+ regulatory T cells inhibit immune-mediated transgene rejection. Blood 102 (2003), 4326–4328.
41. 41 Moghimi, B, Sack, BK, Nayak, S, Markusic, DM, Mah, CS, Herzog, RW, Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 9 (2011), 1524–1533.
42. 42 Nayak, S, Sarkar, D, Perrin, GQ, Moghimi, B, Hoffman, BE, Zhou, S, et al. Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. Front Microbiol, 2, 2011, 244.
43. 43 Qureshi, OS, Zheng, Y, Nakamura, K, Attridge, K, Manzotti, C, Schmidt, EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332 (2011), 600–603.
44. 44 Sack, BK, Merchant, S, Markusic, DM, Nathwani, AC, Davidoff, AM, Byrne, BJ, et al. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS ONE, 7, 2012, e37671.
45. 45 Mueller, C, Chulay, JD, Trapnell, BC, Humphries, M, Carey, B, Sandhaus, RA, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest 123 (2013), 5310–5318.
46. 46 Ferreira, V, Twisk, J, Kwikkers, KL, Aronica, E, Brisson, D, Methot, J, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of Lipoprotein Lipase deficiency (LPLD) gene therapy. Hum Gene Ther 25 (2014), 180–188.
47. 47 Cao, O, Hoffman, BE, Moghimi, B, Nayak, S, Cooper, M, Zhou, S, et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 17 (2009), 1733–1742.
48. 48 Haribhai, D, Lin, W, Relland, LM, Truong, N, Williams, CB, Chatila, TA, et al. Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol 178 (2007), 2961–2972.
49. 49 Rogers, GL, Martino, AT, Zolotukhin, I, Ertl, HC, Herzog, RW, Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med, 12, 2014, 25.
50. 50 Arruda, VR, Schuettrumpf, J, Herzog, RW, Nichols, TC, Robinson, N, Lotfi, Y, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103 (2004), 85–92.
51. 51 Ayuso, E, Mingozzi, F, Montane, J, Leon, X, Anguela, XM, Haurigot, V, et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 17 (2010), 503–510.